Clinical Trials Directory

Trials / Completed

CompletedNCT01412073

Control of Blood Loss During Caesarean Section

A Randomized Trial to Determine the Best Strategy for the Control of Blood Loss at Elective Caesarean Section

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
600 (actual)
Sponsor
Cairo University · Academic / Other
Sex
Female
Age
25 Years – 40 Years
Healthy volunteers
Accepted

Summary

trial of 3 protocols to determine the best one to control blood loss during caesarean section

Detailed description

The study population will be divided into 3 groups each containing 200 women: Group (A): 200 patients will receive 5-IU oxytocin bolus over 3 minutes after delivery of the baby. Group (B): 200 patients will receive 5-IU oxytocin bolus over 3 minutes and 30-IU oxytocin infusion in 500 ml 0.9 % saline over 4 hours after delivery of the baby. Group (C): 200 patients will receive misoprostol 800 micrograms intrauterine, placed manually on the bottom of the uterine cavity after delivery of the placenta and cleaning of the cavity. Operative blood loss will be estimated in theatre based on the volume in the suction bottle and the weight of swabs used. We will record blood loss up until the time the woman will be discharged from the theatre recovery ward. Hemoglobin level and haematocrit value will be done as follow:- 1. After admission of each case in the pre-operative period. 2. Immediately post- operative. 3. 24 hours post- operative.

Conditions

Interventions

TypeNameDescription
DRUGoxytocingroup I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours
DRUGMisoprostolmisoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby \& the placenta

Timeline

Start date
2011-09-01
Primary completion
2014-09-01
Completion
2014-10-01
First posted
2011-08-08
Last updated
2014-10-07

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT01412073. Inclusion in this directory is not an endorsement.